Fair to expect a 1-2B$US valuation at takeover time GEHC will most probably be the one to buyout VPT at the CEO George Adam's projected 2 billion USD valuation in 2023
Dr. Adams once mentioned 2-3 years ago that if he was a medical manufacturer company, with a finished product like VMS and with growing sales, he would be worth approx. 1.5B$US. We know that Dr. Adams masters his environment and knows the real valuation of things in his market. Now, one poster brings back similar quote from Dr. Adams (2B$US this time).
We're currently being valued at 34M$US (@0.21$US/share) (44M$CAN (@0.285$CAN/share)).
Fully diluted, we stand @182M shares (170M TSO).
So instead of the 2B$US target, lets assume 1B$US, to play it conservative. That's a 30x bagger. That would bring the share price @6.30$US (8.55$CAN).
No matter how we slice it, there's ample room on the upside.
What will get us there:
- We know that, once GEHC launches its Edison platform, we'll have instantly access to 40% of the market. That will get us instantly huge visibility and so, generate huge royalties, usage fees, etc .... Revenues will inevitably spike the share price.
- In the meantime, Dr. Adams is very active in signing additional distribution deals like those of CardioLogic Ltd. and AngioPro (both leading distributors of medical devices for cardiac care) in other geos (Brazil, Europe, Middle East, etc ...) to address the remaining (60%) of the market. This will also add sales over time.
- VPT was present at 11 conferences this year alone. So lets assume the same amount in 2023. This has already converted into solid leads.
So at one point in time, sales will kick in from many angles. So the recent upgrade of their location so they can assemble up to 20 VMS 3.0/week, 1,000/year.
Again, Dr. Adams is a serial entrepreneur that has a deep understanding of his environment and the market, is a brilliant deal maker, has been on both side of the fence. And we know this company will be for sale at his conditions. No fire sales.
Below, here's an Oct. 2022 presentation on why VPT answers a real need in cardiology;
Ventripoint to Manage Children with Congenital Heart Disease by Dr Greg Skinner